MarketCap
Danaher Corporation DHR
$ 232.05
1.83%
Facebook
X
Telegram
Danaher Corporation Revenue | DHR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Danaher Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.6 B | 23.9 B | 23.9 B | 26.6 B | 24.8 B | 22.3 B | 17.9 B | 19.9 B | 18.3 B | 16.9 B | 20.6 B | 19.9 B | 19.1 B | 18.3 B | 16.1 B | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 26.6 B | 16.1 B | 20.9 B |
Quarterly Revenue Danaher Corporation
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.05 B | 5.94 B | 5.74 B | 6.55 B | 5.8 B | 5.74 B | 5.8 B | - | 5.62 B | 5.91 B | 5.8 B | 6.53 B | 7.66 B | 7.75 B | 7.69 B | - | - | 7.75 B | 7.69 B | - | 7.23 B | 7.22 B | 6.86 B | - | 5.88 B | 5.3 B | 4.34 B | 4.87 B | 4.38 B | 4.44 B | 4.22 B | 5.36 B | 4.85 B | 4.98 B | 4.7 B | 5.09 B | 4.53 B | 4.51 B | 4.21 B | 4.58 B | 4.13 B | 4.24 B | 3.92 B | 4.32 B | 3.51 B | 4.96 B | 4.69 B | 5.22 B | 4.71 B | 4.96 B | 4.66 B | 5.04 B | 4.67 B | 4.74 B | 4.44 B | 4.98 B | 4.42 B | 4.55 B | 4.32 B | 4.72 B | 4.45 B | 3.64 B | 3.29 B |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.75 B | 3.29 B | 5.24 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Thermo Fisher Scientific
TMO
|
44.6 B | $ 680.21 | 0.92 % | $ 256 B |  USA |
 |
NeoGenomics
NEO
|
727 M | $ 16.79 | 1.21 % | $ 2.15 B | USA |
 |
Trinity Biotech plc
TRIB
|
61.6 M | $ 7.3 | -0.06 % | $ 2.62 B |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
377 M | $ 145.71 | 4.14 % | $ 8.71 B | USA |
 |
VolitionRx Limited
VNRX
|
1.73 M | $ 0.18 | 3.1 % | $ 22.6 M |  Singapore |
 |
QIAGEN N.V.
QGEN
|
2.09 B | $ 50.5 | 0.21 % | $ 11 B |  Niderland |
 |
Waters Corporation
WAT
|
932 M | $ 455.26 | 0.41 % | $ 27.1 B | USA |
 |
Exagen
XGN
|
66.6 M | $ 7.47 | 2.75 % | $ 161 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Brainsway Ltd.
BWAY
|
41 M | $ 11.06 | -1.69 % | $ 376 M |  Israel |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Anixa Biosciences
ANIX
|
210 K | $ 2.93 | -2.01 % | $ 95.1 K | USA |
 |
Biodesix
BDSX
|
88.5 M | $ 21.24 | 0.28 % | $ 160 M | USA |
 |
BioNano Genomics
BNGO
|
28.5 M | $ 1.16 | 2.65 % | $ 6.32 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
DarioHealth Corp.
DRIO
|
22.4 M | $ 3.79 | 0.53 % | $ 15.1 M | Israel |
 |
Personalis
PSNL
|
69.6 M | $ 15.93 | 0.5 % | $ 1.42 B | USA |
 |
Quidel Corporation
QDEL
|
1.66 B | $ 13.5 | -1.68 % | $ 569 M | USA |
|
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
7.66 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
Aspira Women's Health
AWH
|
343 K | - | -6.19 % | $ 10.5 M | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | - | - | $ 19.8 B | USA |
 |
Interpace Biosciences
IDXG
|
38.7 M | $ 6.47 | 2.11 % | $ 28.6 M | USA |
 |
Organovo Holdings
ONVO
|
131 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
30.2 M | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
2.86 B | - | -0.91 % | $ 14.7 B | USA |
 |
Soleno Therapeutics
SLNO
|
190 M | - | - | $ 2.69 B | USA |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Biomerica
BMRA
|
4.45 M | $ 1.73 | 2.98 % | $ 5.04 M | USA |
 |
Myriad Genetics
MYGN
|
824 M | $ 5.93 | 1.87 % | $ 549 M | USA |
 |
Pacific Biosciences of California
PACB
|
160 M | $ 2.27 | 7.58 % | $ 681 M | USA |
 |
Neuronetics
STIM
|
149 M | $ 2.24 | 5.92 % | $ 148 M | USA |
 |
Agilent Technologies
A
|
6.95 B | $ 175.71 | 1.56 % | $ 49.9 B | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 354.37 | 2.67 % | $ 17.6 B | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
126 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
5.39 B | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K | Israel |
 |
Burning Rock Biotech Limited
BNR
|
540 M | $ 11.95 | 1.1 % | $ 126 M | China |
 |
Renalytix AI plc
RNLX
|
2.29 M | - | 5.66 % | $ 22.7 M | Britain |
 |
Bioventus
BVS
|
568 M | $ 14.71 | -1.67 % | $ 980 M | USA |
 |
Psychemedics Corporation
PMD
|
19.7 M | - | -1.84 % | $ 15.3 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
17.8 B | $ 26.77 | -0.48 % | $ 25.4 B | Niderland |
 |
Meridian Bioscience
VIVO
|
333 M | - | - | $ 1.49 B | USA |
 |
Accelerate Diagnostics
AXDX
|
11.7 M | - | -61.36 % | $ 2.46 M | USA |